AryoGen

AryoGen
Company typePrivate Company
IndustryPharmaceutical
Founded2009
Headquarters
Tehran
,
Iran
Area served
Worldwide
Key people
Fereidoun Mahboudi
Chairman
Productsbiopharmaceuticals, Monoclonal antibody
RevenueIncrease US$ 100 million
Number of employees
Increase 300+ (2015)
WebsiteAryoGen

AryoGen Pharmed (Persian: آریوژن فارمد) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]

History

AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was spun off a Biopharmaceutical company, which formed a new entity named AryoGen Pharmed which started its production in 2011. It was deemed an issue of national interest. AryoGen changed its name to AryoGen Pharmed in 2016.

AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified.[4]

Inside Aryogen, production line for AryoSeven
Inside Aryogen, production line for AryoSeven

Products

AryoGen's products include:

AryoSeven is now approved by Iranian food and drug organisation and from August 2012 is in the market.

22000 sqm AryoGen Biopharma complex in a panorama photo
AryoGen Pharmed Complex.

See also

References

  1. ^ "IRAN, ISLAMIC REPUBLIC OF : Aryogen produces locally made medicines in Iran; helps Iran save up to $100 mln annually". Mena Report. Archived from the original on 2014-10-01.
  2. ^ World's 2nd factor VII factory opened in Iran. - Mehr News Agency (MNA) | HighBeam Research
  3. ^ Iran launches domestic manufacture of anti-hemophilia drug - Trend.Az
  4. ^ "MENA mAb manufacturer AryoGen receives EU GMP approval / Pharma News / Home - GaBI Online - Generics and Biosimilars Initiative". www.gabionline.net. Retrieved 2019-06-11.